Russell Investments Group Ltd. Has $2.10 Million Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Russell Investments Group Ltd. grew its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 60.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 265,927 shares of the company's stock after purchasing an additional 99,807 shares during the period. Russell Investments Group Ltd. owned approximately 0.09% of Amneal Pharmaceuticals worth $2,100,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in AMRX. State Street Corp boosted its holdings in Amneal Pharmaceuticals by 3.8% during the third quarter. State Street Corp now owns 3,514,721 shares of the company's stock worth $29,242,000 after buying an additional 127,753 shares in the last quarter. Wellington Management Group LLP bought a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter worth $687,000. Barclays PLC grew its holdings in shares of Amneal Pharmaceuticals by 134.1% in the 3rd quarter. Barclays PLC now owns 296,384 shares of the company's stock worth $2,466,000 after acquiring an additional 169,756 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Amneal Pharmaceuticals by 11.1% during the third quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company's stock worth $31,511,000 after purchasing an additional 378,136 shares during the period. Finally, Franklin Resources Inc. lifted its holdings in shares of Amneal Pharmaceuticals by 4.9% during the third quarter. Franklin Resources Inc. now owns 89,887 shares of the company's stock valued at $778,000 after purchasing an additional 4,178 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on AMRX. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $9.00 to $12.00 in a report on Monday, February 24th. Barclays boosted their price target on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a report on Monday, March 3rd. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $10.80.

Insider Activity

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.90, for a total value of $712,000.00. Following the completion of the sale, the director now directly owns 1,808,886 shares in the company, valued at $16,099,085.40. The trade was a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the stock in a transaction on Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the transaction, the insider now owns 48,578,209 shares in the company, valued at approximately $405,628,045.15. This trade represents a 9.33 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,160,000 shares of company stock worth $43,113,200 in the last three months. 17.45% of the stock is owned by insiders.

Amneal Pharmaceuticals Price Performance

Amneal Pharmaceuticals stock traded up $0.11 during trading hours on Thursday, hitting $7.41. The company had a trading volume of 192,653 shares, compared to its average volume of 1,406,033. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $5.56 and a fifty-two week high of $9.48. The firm has a market capitalization of $2.30 billion, a P/E ratio of -10.89 and a beta of 1.06. The firm's fifty day moving average is $8.07 and its 200-day moving average is $8.21.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The company had revenue of $730.52 million during the quarter, compared to analyst estimates of $708.21 million. During the same period last year, the company posted $0.14 earnings per share. Analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.